Publication | Closed Access

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

OncologyPathologyCancer TreatmentCancer GeneticsMedicineRadiation OncologyLung CancerMolecular OncologyOverall Survival Results